Cargando…
Platelet activating factor levels and metabolism in tangier disease: a case study
BACKGROUND: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was fou...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499335/ https://www.ncbi.nlm.nih.gov/pubmed/22769014 http://dx.doi.org/10.1186/1476-511X-11-89 |
_version_ | 1782249943127293952 |
---|---|
author | Kolovou, Vana Papakonstantinou, Vasiliki D Stamatakis, George Verouti, Sophia N Xanthopoulou, Marianna N Kolovou, Genovefa Demopoulos, Constantinos A |
author_facet | Kolovou, Vana Papakonstantinou, Vasiliki D Stamatakis, George Verouti, Sophia N Xanthopoulou, Marianna N Kolovou, Genovefa Demopoulos, Constantinos A |
author_sort | Kolovou, Vana |
collection | PubMed |
description | BACKGROUND: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A(2) (Lp-PLA(2)) in plasma and regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for 50% aggregation (EC(50)) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and thrombin, and the activities of PAF metabolic enzymes Lp-PLA(2), PAF-AH, Lyso-PAF-AT and PAF-CPT. METHODS: The EC(50) value of PRP was measured by an aggregometer. The determination of the specific activity of PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA(2) was made after an in vitro enzymatic assay from the decay of radioactive PAF. RESULTS: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA(2) activity in plasma compared to healthy women. The EC(50) of PAF and Thrombin were higher compared to healthy women. CONCLUSION: The increased Lp-PLA(2) activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain the decreased bound-PAF level in TD patient and the EC(50) of PAF. However, total PAF is in a normal range and this probably can explain one of the reasons this TD patient has no CAD. |
format | Online Article Text |
id | pubmed-3499335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34993352012-11-16 Platelet activating factor levels and metabolism in tangier disease: a case study Kolovou, Vana Papakonstantinou, Vasiliki D Stamatakis, George Verouti, Sophia N Xanthopoulou, Marianna N Kolovou, Genovefa Demopoulos, Constantinos A Lipids Health Dis Research BACKGROUND: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A(2) (Lp-PLA(2)) in plasma and regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for 50% aggregation (EC(50)) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and thrombin, and the activities of PAF metabolic enzymes Lp-PLA(2), PAF-AH, Lyso-PAF-AT and PAF-CPT. METHODS: The EC(50) value of PRP was measured by an aggregometer. The determination of the specific activity of PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA(2) was made after an in vitro enzymatic assay from the decay of radioactive PAF. RESULTS: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA(2) activity in plasma compared to healthy women. The EC(50) of PAF and Thrombin were higher compared to healthy women. CONCLUSION: The increased Lp-PLA(2) activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain the decreased bound-PAF level in TD patient and the EC(50) of PAF. However, total PAF is in a normal range and this probably can explain one of the reasons this TD patient has no CAD. BioMed Central 2012-07-08 /pmc/articles/PMC3499335/ /pubmed/22769014 http://dx.doi.org/10.1186/1476-511X-11-89 Text en Copyright ©2012 Kolovou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kolovou, Vana Papakonstantinou, Vasiliki D Stamatakis, George Verouti, Sophia N Xanthopoulou, Marianna N Kolovou, Genovefa Demopoulos, Constantinos A Platelet activating factor levels and metabolism in tangier disease: a case study |
title | Platelet activating factor levels and metabolism in tangier disease: a case study |
title_full | Platelet activating factor levels and metabolism in tangier disease: a case study |
title_fullStr | Platelet activating factor levels and metabolism in tangier disease: a case study |
title_full_unstemmed | Platelet activating factor levels and metabolism in tangier disease: a case study |
title_short | Platelet activating factor levels and metabolism in tangier disease: a case study |
title_sort | platelet activating factor levels and metabolism in tangier disease: a case study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499335/ https://www.ncbi.nlm.nih.gov/pubmed/22769014 http://dx.doi.org/10.1186/1476-511X-11-89 |
work_keys_str_mv | AT kolovouvana plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy AT papakonstantinouvasilikid plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy AT stamatakisgeorge plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy AT veroutisophian plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy AT xanthopouloumariannan plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy AT kolovougenovefa plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy AT demopoulosconstantinosa plateletactivatingfactorlevelsandmetabolismintangierdiseaseacasestudy |